Taipei Exchange - Delayed Quote TWD

Anya (7776.TWO)

35.95
+0.85
+(2.42%)
At close: May 29 at 2:57:57 PM GMT+8
Loading Chart for 7776.TWO
  • Previous Close 35.10
  • Open 35.15
  • Bid 35.40 x --
  • Ask 36.00 x --
  • Day's Range 35.00 - 36.00
  • 52 Week Range 19.95 - 82.30
  • Volume 52,009
  • Avg. Volume 66,807
  • Market Cap (intraday) 1.765B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.12
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Anya Biopharm Inc., a pharmaceutical company, develops platform for oral peptides. The company is based in Taipei, Taiwan.

anyabiopharm.com

--

Full Time Employees

--

Fiscal Year Ends

Recent News: 7776.TWO

View More

Performance Overview: 7776.TWO

Trailing total returns as of 5/29/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

7776.TWO
4.52%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
7.33%

1-Year Return

7776.TWO
37.91%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
1.46%

3-Year Return

7776.TWO
37.91%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
31.24%

5-Year Return

7776.TWO
37.91%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
95.09%

Compare To: 7776.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 7776.TWO

View More

Valuation Measures

Annual
As of 5/29/2025
  • Market Cap

    1.77B

  • Enterprise Value

    1.31B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    81.74

  • Price/Book (mrq)

    3.78

  • Enterprise Value/Revenue

    60.84

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    -1.12

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 7776.TWO

View More

Company Insights: 7776.TWO

Research Reports: 7776.TWO

View More